 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Drug:
|
ABBF (EVP6124)
|
|
Mode of action:
|
α7 nAChR agonist
|
|
Phase:
|
POC Successful
|
|
Company:
|
EnVivo Pharmaceuticals
|
|
Note:
|
Add-on for cognitive deficit; licensed in from Bayer
|
Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess
FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M,
Bertrand S, Bertrand D, König G. EVP-6124, a novel and
selective a7 nicotinic acetylcholine receptor partial
agonist, improves memory performance by potentiating the
acetylcholine response of a7 nicotinic acetylcholine
receptors. Neuropharmacology . 2012 Feb ; 62(2):1099-110. Abstract
Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J,
Methfessel C, Riedl B, Schnizler K, van der Staay FJ, van
Kampen M, Wiese WB, Koenig G. The novel alpha7 nicotinic
acetylcholine receptor agonist
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide
improves working and recognition memory in rodents. J
Pharmacol Exp Ther . 2007 May 1 ; 321(2):716-25. Abstract
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: